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Abstract: The harmful effects of coronavirus disease 2019 (COVID-19) can reach the autonomic nervous
system (ANS) and endothelial function. Therefore, the detrimental multiorgan effects of COVID-19 could
be induced by deregulations in ANS that may persist after the acute SARS-CoV-2 infection. Additionally,
investigating the differences in ANS response in overweight/obese, and physically inactive participants
who had COVID-19 compared to those who did not have the disease is necessary. The aim of the
study was to analyze the autonomic function of young adults after mild-to-moderate infection with
SARS-CoV-2 and to assess whether body mass index (BMI) and levels of physical activity modulates
autonomic function in participants with and without COVID-19. Patients previously infected with
SARS-CoV-2 and healthy controls were recruited for this cross-sectional observational study. A general
anamnesis was taken, and BMI and physical activity levels were assessed. The ANS was evaluated
through heart rate variability. A total of 57 subjects were evaluated. Sympathetic nervous system activity
in the post-COVID-19 group was increased (stress index; p = 0.0273). They also presented lower values of
parasympathetic activity (p < 0.05). Overweight/obese subjects in the post-COVID-19 group presented
significantly lower parasympathetic activity and reduced global variability compared to non-obese in
control group (p < 0.05). Physically inactive subjects in the post-COVID-19 group presented significantly
higher sympathetic activity than active subjects in the control group. Parasympathetic activity was
significantly increased in physically active subjects in the control group compared to the physically
inactive post-COVID-19 group (p < 0.05). COVID-19 promotes changes in the ANS of young adults, and
these changes are modulated by overweight/obesity and physical activity levels.
Keywords: COVID-19; autonomic nervous system; heart rate; obesity; exercise
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1. Introduction
Coronavirus disease (COVID-19) is a recognized infectious disease caused by SARS-CoV-2
infection that has rapidly spread worldwide, reaching a pandemic level in 2020. COVID-19
was reported in over 170 countries and has brought unprecedented morbidity, mortality,
and disruption globally [1,2]. Despite severe complications that may be caused by the virus,
a significantly high number of individuals did not require intensive care and continue to
present sequelae months after the COVID-19 diagnosis [3].
Although COVID-19 is primarily manifested as a respiratory disease, many studies
have shown that it is a systemic infection involving multiple systems and affecting individuals of all ages [2,4]. Initial studies showed that the harmful effects of COVID-19 could
also reach the autonomic nervous system (ANS), even in non-hospitalized young individuals. Interestingly, detection of SARS-CoV-2 in carotid body of severe COVID-19 patients
was previously reported, and its involvement may explain silent hypoxemia, a route of
nervous system invasion and ANS deregulation [5–7]. It is hypothesized that autonomic
dysfunction after COVID-19 infection could be mediated by the virus itself [8], or even
associated with the cytokine storm response, resulting in oxidative stress. These mediators
can subsequently cross the blood–brain barrier, ultimately increasing the activation of the
sympathetic nervous system (SNS) [6,9]. Furthermore, autonomic dysfunction has also
been shown to be associated with COVID-19 severity and prognosis [4].
Further investigations to clarify the impact of COVID-19 on ANS are needed as the
ANS plays a major role in regulating the body’s homeostasis. Any dysfunction in this
system can have detrimental effects on several physiological systems, including alterations
in the cardiovascular system and the immune, hematological, and renal systems [10].
Additionally, a sympathetic overdrive has been identified as an independent predictor of
mortality in several diseases [11–13]. Koopman et al., in an epidemiological study, observed
that low cardiac autonomic modulation was associated with higher chances of mortality in
individuals with low cardiovascular risk [14].
The autonomic imbalance may persist after acute SARS-CoV-2 infection, and the
burden of several post-COVID-19 conditions, including postural orthostatic tachycardia syndrome (POTS), dysautonomia, fatigue, cerebral hypoperfusion syndrome, and
impaired endothelial function, are associated with this condition independently of hospitalization [6,15,16]. A recent clinical case study reported strong benefits of invasive
vagus nerve stimulation, such as relief of chest tightness and shortness of breath, in
COVID-19 patients [17]. In fact, patients presenting post-viral condition, such as myalgic
encephalomyelitis, induced by several viruses, manifest several alterations in ANS with
harmful impact in the health and body homeostasis [18–20]. Thus, the ANS dysfunction
after acute SARS-CoV-2 may be not necessarily new, but an old sequela observed in several
post-viral infectious episodes.
It is well established that other factors can directly affect autonomic function, such
as obesity [21,22] and levels of physical activity [23,24]. Recent investigations indicate
that obesity is associated with poor prognosis for SARS-CoV-2 infection, intensive care
hospitalization, and disease progression [25,26]. Additionally, each 1-unit increase in body
mass index (BMI) might be related to a 12% increase in the risk of severe COVID-19. These
alterations can be associated with chronic low-grade inflammation and impairments in
immune cell activation of obese patients [25,27]. However, it is necessary to investigate if
overweight and obesity can cause additional changes to the ANS after COVID-19 infection.
On the other hand, according to the World Health Organization, physical activity
offers significant health benefits and mitigates health risks [28,29]. As a result, adults
aged between 18 to 64 years should undertake at least 150 min of moderate- or 75 min
of vigorous-intensity physical activity, or an equivalent combination of them per week
to prevent detrimental effects on health outcomes [28]. The role of physical activity is
still under investigation after COVID-19 infection, although sufficient physical activity
decreases the prevalence of COVID-19-related hospitalization [30]. Therefore, it is important
to understand if physical activity can play a protective role on the ANS after SARS-CoV-2
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infection. Antagonic effects of BMI and physical activity were observed in the management
of neurocognitive and fatigue symptoms, and in the incidence of post-acute sequelae
SARS-CoV-2 infection (PASC) in healthcare workers [31].
This information is extremely relevant to help health professionals screen patients
with COVID-19 presenting additional risk factors and educate and inform the global
population of the factors that can influence the clinical course of this widespread disease.
Persistent symptoms and physiological alterations associated with PACS impact physical
and cognitive function and health-related quality of life, and there is a need to clarify
the pathophysiological mechanisms of post-COVID-19 syndrome in young individuals
previously infected by SARS-CoV-2 that do not require acute hospitalization.
The present study adds novelty and relevant aspects to the literature since it (1) investigates
cases after mild to moderate COVID-19 infection in young adults, a subgroup of patients
who are often overlooked, that did not require intensive care, addressing the influence
of obesity and physical activity after COVID-19 infection on the ANS (2) through the
estimation of the heart rate variability (HRV), a reliable and noninvasive method [32]. To
our knowledge, these data are not yet available in the literature.
Thus, the primary aim of the study was to analyze the autonomic function of young
adults after mild to moderate infection by COVID-19. Second, we aimed to identify the
influence of body mass index (BMI) and levels of physical activity on the autonomic
function in these individuals, indexed to the HRV indicators.
2. Materials and Methods
2.1. Ethical Approval
The study followed the ethical standards described by the Declaration of Helsinki.
Additionally, all participants were notified about the study purpose and protocols and
gave written informed consent to the protocols. The Ethical Institutional Review Board
approved the study (approval number: 38701820.0.0000.5402).
2.2. Study Design
This is a cross-sectional observational study that is part of a broader research project:
FIT-COVID Study [33]. The study was previously registered at the Brazilian Clinical Trials
Registry (registration number: RBR-5dqvkv3). All reports followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) guidelines [34].
Patients that were infected with COVID-19 were recruited to participate in the study
through local media (TV, radio) and social media and via electronic access to participants’
database of the Municipal Health Secretariat of Presidente Prudente São Paulo, Brazil
(231,953 inhabitants; human development index, 0.806; 23,657 confirmed COVID-19 cases,
moving average of 135 cases (May 2021)). We included male and female patients, aged
20–40 years after mild or moderate clinical COVID-19 with a previous positive PCR test and
infection including slight clinical symptoms, fever, or respiratory symptoms, and that were
not admitted to the intensive care unit. Participants were recruited after a minimum of 15
and maximum of 180 days of diagnosis by positive PCR test [35]. An age-matched healthy
control group that was negative for COVID-19 was also recruited. To screen for confirmed
or probable previous SARS-CoV-2 infection for the control group, a lateral flow test for IgM
and IgG antibodies was conducted using internal anti-SARS-CoV-2 Immunoglobulin G
(IgG) and Immunoglobulin M (IgM) ELISA kits.
The exclusion criteria were as follows: (1) presence of any chronic noncommunicable
diseases, (2) smokers, (3) history of drug use, (4) medications such as anti-inflammatory
drugs, antibiotics, and others known for their impact over the ANS, individuals that were
vaccinated for COVID-19 and (5) patients that received intensive care.
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2.3. Experimental Measures
2.3.1. Initial Evaluation
A general anamnesis was taken, including sociodemographic characteristics and selfrated health and medical history (family comorbidities, cardiopulmonary symptoms, and
medication use). Symptoms that emerged during acute COVID-19 infection and persistent
symptoms were also evaluated. Participants were also assessed regarding their BMI and
physical activity level. Finally, blood pressure tests after 20 min of rest were also performed
using auscultatory blood pressure measurement [36].
2.3.2. Body Mass Index
BMI was calculated according to previous literature. We considered BMI as the ratio of
weight (kg) to height (m) squared. To evaluate the weight of participants, an electronic and
calibrated scale (Kratos-Cas, São Paulo, SP, Brazil) was used with individuals wearing light
clothes and barefoot. Height was measured using a portable anthropometer (Kratos-Cas,
São Paulo, SP, Brazil) [37].
2.3.3. Physical Activity Level
The level of physical activity was measured using a triaxial accelerometer (GT3X+;
ActiGraph, LLC, Pensacola, FL, USA). Participants were instructed to wear the accelerometer above the waist for seven consecutive days during waking hours. A minimum of
four days with at least 10 h/day was defined as valid accelerometer data. Participants
were instructed not to use the accelerometer while bathing, sleeping, or performing water
activities. Moreover, every morning, a researcher sent a WhatsApp message reminding the
participant to use the accelerometer.
Non-wear periods were defined as time intervals of at least 60 consecutive minutes
of zero counts, with an activity interruption allowance of 0–100 counts/min lasting a
maximum of 2 consecutive minutes [38]. Counts per minute were calculated using the sum
of the total activity counts in the vertical axis divided by the valid days. Sedentary time
was defined as values <100 counts/min, light physical activity as values between 100 and
2019 counts/min, and moderate–vigorous physical activity as values >2020 counts/min.
Data were processed using the ActLife software (version 6.9.2, Pensacola, FL, USA) [39].
2.3.4. Heart Rate Variability
ANS function was measured through HRV, which is considered a simple, dependable,
inexpensive, and noninvasive method [32]. For this evaluation, participants were asked
to attend an outpatient clinic in a fasted state, having abstained from exercise, caffeine,
chocolate, and alcohol for at least 24 h before evaluation and ≥4 h after a snack or light
meal. Evaluations were performed in a silent space, with temperature of ∼23 ◦ C. HRV
analysis was undertaken in the morning to avoid circadian changes [32].
Heart rate was recorded beat-to-beat to evaluate cardiac autonomic modulation. We
used a cardio-frequency meter (Polar RS800CX, Polar Electro, Kempele, Finland) at a 1 kHz
sampling rate. Participants were sited with a chest strap and monitor and remained at
rest with spontaneous breathing for 25 min. HRV was performed on 256 consecutive
intervals between successive heartbeats (RR intervals) from the most stable segment on the
tachogram. Only series with <5% error were considered suitable for analysis. Kubios HRV®
software (Biosignal Analysis and Medical Image Group, Department of Physics, University
of Kuopio, Finland) was used to complete the HRV analysis [40,41].
The HRV was assessed in both the time and frequency domains. For the time domain,
the mean RR intervals (reflecting global variability) were used. Additionally, the following
indexes were calculated:
The square root of the mean squared difference between adjacent RR intervals (RMSSD)
indicating parasympathetic modulations of the HR.
The standard deviation of all normal RR intervals (SDNN) reflecting global variability.
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Geometric indexes from Poincaré plot SD1 and SD2, indicating parasympathetic and
global modulations of HR, respectively.
Triangular interpolation of normal to normal RR intervals (TINN) indicating global variability.
Triangular index (RRtri), also signifying global variability.
For the frequency domain, spectral analysis was computed using the fast Fourier
transform, and the following indexes were included in the study:
The low-frequency (LF: 0.04 Hz to 0.15 Hz) and high-frequency (HF: 0.15 Hz to
0.4 Hz) components were computed, representing sympathetic and parasympathetic activity, respectively. The LF to HF (LF/HF) ratio was calculated as a measure of autonomic
(sympathovagal) balance.
The following indexes computed in Kubios HRV software were also included:
Baevsky’s stress index, a geometric measure of HRV reflecting cardiovascular system stress.
Parasympathetic nervous system index (PNS index) calculated based on the mean RR,
RMSSD, and SD1 in normalized units.
SNS index, calculated based on the mean HR, Baevsky’s stress index, and SD2 in
normalized units [41].
2.4. Statistical Analysis
Statistical procedures were performed using GraphPad Prism (version 5.00; GraphPad
Software, San Diego, CA, USA) for Windows. Data distribution was analyzed using the
Shapiro–Wilk test. For the primary analysis of comparisons between the post-COVID-19
and control groups, the unpaired t-test or Mann–Whitney U-test were used according to
data distribution. The Fisher test was performed for categorical variables (sex).
In our secondary analysis, the post-COVID-19 and control groups were categorized according to the BMI, dividing each group into eutrophic (<25 kg/m2 ) and overweight/obese
(≥25.0 kg/m2 ). Moreover, the groups were analyzed according to levels of physical activity,
considering the subjects with <150 min of moderate to vigorous physical activity (MVPA)
and subjects with ≥150 min of MVPA in each group [28]. All secondary analyses were
performed using the one-way analysis of variance or Kruskal–Wallis test according to data
distribution. Effect sizes (ESs) were calculated for significant secondary comparisons and
classified as negligible (<0.01), small (0.1–0.29), medium (0.3–0.49), and large (>0.5) [42].
Additionally, binary logistic regression analysis was employed to identify factors
associated with presence of post-COVID-19 and HRV indexes. Univariate and multivariate
logistic regression were performed to test the association between the dependent and the
independent variables.
Correlational analysis between the number of reported symptoms in the post-COVID-19
group and the HRV index was performed using Pearson or Spearman test according to
data distribution. Independent variables that presented statistical correlation were inserted
in a model of linear regression analysis. p-values < 0.05 were considered significant.
3. Results
For this study, 57 subjects were evaluated. After 19 exclusions due to errors in HRV
recordings, 38 subjects with complete data were included in the final analysis. Figure 1
shows the flow diagram of the number of individuals at each stage of the study. In the
post-COVID-19 group, nine subjects were women, and 11 were men. In the control group,
13 subjects were men, and 5 were women.
Patients in the post-COVID-19 group were evaluated 48.45 ± 31.41 days after testing
positive for COVID-19. These individuals were classified as mild (n = 15; 75%) and moderate
(n = 5; 25%) cases [43]. A mean of 5.75 ± 2.61 symptoms (clinical and respiratory) was
noted. The main symptoms reported, and their respective prevalence, were respiratory
symptoms (n = 15; 75%), headache (n = 14; 70%), body pain (n = 14; 70%), anosmia (n = 10;
50%), ageusia (n = 9; 45%), fever (n = 6; 30%), and diarrhea (n = 5; 25%).
No differences in sex distribution were observed between the groups (p = 0.3276). As
indicated in Table 1, the groups were uniformly distributed (p > 0.05) in terms of their
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descriptive characteristic data, except for light physical (p = 0.0444) and vigorous activities
(p = 0.0380).

Figure 1. Flow diagram of the study.
Table 1. Sample characterization between groups. Data with normal distribution are expressed
as mean and standard deviation and data with non-normal distribution as median and 25–75%
interquartile range.
Groups
Variables
Sex (F/M)
Age (years)
Weight (kg)
Height (m)
BMI (kg/m2 )
Systolic blood pressure
Diastolic blood pressure
Sedentary activity
(min/day)
Light activity (min/day)
Moderate activity
(min/day)
Vigorous activity
(min/day)
MVPA (min/day)

Control
Mean/
Median

Post-COVID-19
SD/IQR

Mean/
Median

SD/IQR

Diff between
Means

95%CI

p-Value

(5/13)
26.22
74.59
1.69
24.67
120.00
80.00

5.22
17.32
0.09
4.79
120–120
80–80

(9/11)
29.17
76.57
1.73
26.76
120.00
80.00

6.32
14.36
0.08
5.12
120–130
80–80

−2.95 ± 1.89
−1.98 ± 5.14
−0.03 ± 0.02
−2.09 ± 1.61
8.55 ± 5.02
0.05 ± 1.06

−0.89 to 6.80
−8.45 to 12.42
−0.09 to 0.01
−1.18 to 5.36
−1.64 to 18.75
−2.11 to 2.22

0.3276
0.1276
0.7023
0.1712
0.2039
0.1189
0.9588

578.40

534.90–676.70

499.60

467.10–593.50

55.99 ± 97.31

−254.70 to 142.70

0.5693

239.00

65.15

309.00

116.5

−70.01 ± 33.37

1.87 to 138.10

0.0444 *

17.90

5.10–29.90

13.36

9.25–33.72

0.03 ± 8.05

−16.48 to 16.41

0.9966

3.64

0.0–15.80

0.00

0.00–0.50

−7.931 ± 3.04

−14.14 to −1.72

0.0380 *

23.72

12.60–46.00

14.79

9.57–34.04

8.58 ± 9.94

−28.89 to 11.72

0.3964

m2 ,

SD, standard deviation; IQR, interquartile range, F, female, M, male; kg, kilogram;
square meter; min, minutes;
BMI, body mass index; MVPA, moderate to vigorous physical activities. * Statistical significance (p < 0.05) between
the post-COVID-19 and control groups

Table 2 and Figure 2 illustrate the primary analysis of the study, showing intergroup
comparisons between HRV indexes in the post-COVID-19 and control groups. For the SNS
activity, the post-COVID-19 group showed significantly increased levels of the stress index
(p = 0.0273).
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Table 2. Comparisons between HRV indexes in the post-COVID-19 and control groups. Data
with normal distribution are expressed as mean and standard deviation and data with non-normal
distribution as median and 25–75% interquartile range.
Groups
Variables
Sympathetic nervous
system activity
Mean HR
Stress index
LF (nu)
SNS index
Parasympathetic nervous
system activity
Mean RR
RMSSD
HF (nu)
pNN50
SD1 (ms)
PNS index
Global variability
SDNN
RR triangular index
TINN
LF/HF
SD2 (ms)

Control

Post-COVID-19

Mean/Median

SD/[IQR]

Mean/Median

SD/[IQR]

Diff between Means

95%CI

p-Value

79.83
13.57
65.49
1.59

8.85
2.72
15.30
0.89

83.85
16.62
66.61
2.37

13.38
4.98
15.65
1.57

4.01 ± 3.72
3.04 ± 1.32
1.12 ± 5.03
0.77 ± 0.44

−3.54 to 11.58
0.35 to 5.72
−9.09 to 11.33
−0.07 to 1.63

0.2882
0.0273 *
0.825
0.0719

738.50
27.40
34.49
6.73
19.35
−1.21

694.0–846.50
23.40–33.15
15.30
3.74–12.50
16.58–23.50
−1.49–(−0.90)

689.50
24.45
33.33
3.41
17.30
−1.60

648.0–800.0
14.40–28.55
15.65
0.25–7.36
10.23–20.25
−2.13–(−0.94)

−25.94 ± 37.00
−7.69 ± 2.88
−1.15 ± 5.03
−4.70 ± 2.23
−5.42 ± 2.04
−0.36 ± 0.23

−101.0 to 49.15
−13.55 to −1.83
−11.36 to 9.05
−9.24 to 0.17
−9.58 to −1.27
−0.83 to 0.11

0.1834
0.0452 *
0.8198
0.055
0.0118 *
0.0845

36.17
9.02
161.30
1.99
47.93

9.59
1.91
34.93
1.47–3.39
11.53

29.13
7.91
135
1.83
38.02

9.37
2.34
40.77
1.11–3.88
12.17

−7.04 ± 3.07
−1.10 ± 0.69
−26.33 ± 12.39
0.57 ± 0.71
−9.91 ± 3.85

−13.29 to −0.79
−2.52 to 0.31
−51.47 to −1.19
−0.86 to 2.01
−17.74 to −2.08

0.0282 *
0.1218
0.0404 *
0.9883
0.0145 *

HR, heart rate; LF, low-frequency component; ms, millisecond; nu, normalized unit; SNS index, sympathetic
nervous system index; RMSSD, root mean square of differences between adjacent normal RR intervals in a time
interval; HF, high-frequency component; pNN50, percentage of adjacent RR intervals with a difference in duration
>50 ms; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term
intervals between consecutive. heartbeats; PNS index, parasympathetic nervous system index; SDNN, standard
deviation of all normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
* Statistical significance (p < 0.05) between post-COVID-19 and control group.

Figure 2. Scatterplot of HRV index comparison between the post-COVID-19 and control groups.
Data are expressed as mean and standard deviation for data with normal distribution and median
and 25–75% interquartile range for data with non-normal distribution. (A) Sympathetic nervous
system activity; (B) parasympathetic nervous system activity; (C) global variability. * Statistical
significance (p < 0.05) between the post-COVID-19 and control groups; RMSSD, root mean square
of differences between adjacent normal RR intervals in a time interval; SD1, standard deviation of
instant beat-to-beat variability; SDNN, standard deviation of all normal RR intervals recorded in a
time interval; TINN, triangular interpolation of NN interval; SD2, standard deviation of the long-term
interval between consecutive heartbeats.
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Analysis of the parasympathetic activity showed that the post-COVID-19 group presented significant lower values of RMSSD (p = 0.0452) and SD1 (p = 0.0118). Additionally,
participants in the post-COVID-19 group also presented lower global variability, reflected
through the SDNN (p = 0.0282), TINN (p = 0.0404), and SD2 (p = 0.0145) indexes.
In an univariable binary logistic regression, the influence of post-COVID-19 on HRV
was analyzed (Appendix A). We observed that the presence of post-COVID0.-19 was
significantly associated (p < 0.05) with sympathetic activity (stress index: OR: 1.22; CI 95%:
1.00 to 1.48; p = 0.041), parasympathetic activity (RMSSD: OR: 0.89; CI 95%: 0.81 to 0.98;
p = 0.026 and SD1: OR:0.85; CI 95%: 0.74 to 0.98; p = 0.027) and global variability (SDNN:
OR: 0.92; CI 95%: 0.85 to 0.99; p = 0.039 and SD2: OR: 0.93; CI 95%: 0.87 to 0.99; p = 0.024).
This data is presented in Appendix A.
In the secondary analysis, the post-COVID-19 and control groups were categorized
into non-obese and overweight/obese, as shown in Table 3 and Figure 3. Overweight/obese
(Ow/Ob) patients in the post-COVID-19 group presented significantly lower parasympathetic activity in the SD1 index (95% confidence interval (CI) = −15.33 to −0.3959; p = 0.0301;
ES post-COVID-19 Ow/Ob vs. post-COVID-19 Non-obese = 0.79; ES post-COVID-19
Ow/Ob vs. control Ow/Ob = 0.92).
Table 3. Comparison of HRV indexes between the post-COVID-19 and control groups according to
the BMI. Data with normal distribution are expressed as mean and standard deviation and data with
non-normal distribution as median and 25–75% interquartile range.
Control
Groups
Variables
Sympathetic
activity
Mean HR
Stress index
LF (nu)
SNS index
Parasympathetic
activity
Mean RR
RMSSD
HF (nu)
pNN50
SD1 (ms)
PNS index
Global variability
SDNN
RR triangular
index
TINN
LF/HF
SD2 (ms)

Non-Obese (n = 10)

Post-COVID-19
Overweight/Obese
(n = 8)

Non-Obese (n = 8)

Overweight/Obese
(n = 12)

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

p-Value

83.10
13.70
61.95
1.82

8.43
3.01
17.65
0.94

75.75
13.41
69.92
1.29

8.03
2.49
11.31
0.76

84.63
14.59
58.42
2.09

14.01
3.20
10.90
1.32

83.33
17.97
72.08
2.55

13.55
5.59
16.31
1.74

0.2421
0.2276
0.1643
0.2184

728.80
28.90
38.03
7.32
20.10
−1.33

79.83
(25.58–35.13)
17.65
(6.00–14.49)
(18.18–24.93)
(−1.53–(−0.92))

800
24.40
30.06
4.45
17.3
−0.97

90.11
(21.00–32.25)
11.3
(0.83–11.40)
(14.93–22.85)
(−1.45–(−0.82))

727.50
26.30
41.54
4.96
18.60
−1.48

141.30
(18.73–33.23)
10.91
(2.04–12.16)
(13.28–23.50)
(−2.08–(−0.95))

739.2
21.25
27.87
1.54
15.05
−1.65

131.4
(9.95–27.53)
16.3
(0–7.07)
(7.075–19.45)
(−2.17–(−0.71))

0.2339
0.0786
0.1142
0.0506
0.0301 *
0.3112

38.22

7.95

33.61

11.34

34.05

8.87

25.85

8.50

0.024 *

9.58

2.26

8.31

1.12

9.04

2.04

7.15

2.29

0.0507

167.20
2.06
49.45

37.96
1.14
10.61

154
2.91
46.03

31.63
1.87
13.06

156.60
1.58
44.38

36.57
0.81
12.20

120.60
3.97
33.78

38.11
3.02
10.6

0.0288 *
0.0605
0.0179 *

HR, heart rate; LF, low-frequency component; ms, millisecond; nu, normalized unit; SNS index, sympathetic
nervous system index; RMSSD, root mean square of differences between adjacent normal RR intervals in a time
interval; HF, high-frequency component; pNN50, percentage of adjacent RR intervals with a difference in duration
>50 ms; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term
intervals between consecutive heartbeats; PNS index, parasympathetic nervous system index; SDNN, standard
deviation of all normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
* Statistical differences between non-obese patients in the control group and overweight/obese patients in the
post-COVID-19 group.

Moreover, these subjects presented with reduced global variability, as shown by SDNN (95%
CI = −23.29 to −1.453; p = 0.024; ES post-COVID-19 Ow/Ob vs. post-COVID-19 Non-obese = 0.94;
ES post-COVID-19 Ow/Ob vs. control Ow/Ob = 0.77), TINN (95% CI = −90.41 to −2.826;
p = 0.0288; ES post-COVID-19 Ow/Ob vs. COVID-19 Eutro = 0.96; ES post-COVID-19 Ow/Ob
vs. control Ow/Ob = 0.94), and SD2 (95% CI = −29.45 to −1.899; p = 0.0179; ES postCOVID-19 Ow/Ob vs. post-COVID-19 Non-obese = 0.92; ES post-COVID-19 Ow/Ob vs.
control Ow/Ob = 1.03) indexes when compared with those in non-obese individuals in the
control group.
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Figure 3. Scatterplot of HRV indexes according to the BMI data with normal distribution are expressed as mean and standard deviation and data with non-normal distribution as median and
25–75% interquartile range. (B) parasympathetic nervous system activity; (C) global variability.
* Statistical differences between groups; SD1, standard deviation of instantaneous beat-to-beat variability; SDNN, standard deviation of all normal RR intervals recorded in a time interval; TINN,
triangular interpolation of NN interval; SD2, standard deviation of long-term intervals between
consecutive heartbeats.

Comparisons between groups were also investigated with regard to the levels of
physical activity, dividing the post-COVID-19 and control groups according to the MVPA
(≥150 min and <150 min), as shown in Table 4 and Figure 4.
Physically inactive subjects (<150 min of MVPA) in the post-COVID-19 group presented
with significantly higher levels of stress index compared to those in active subjects in the
control group (0.0147; ES post-COVID-19 < 150 min vs. post-COVID-19 ≥ 150 min = 0.94; ES
post-COVID-19 < 150 min vs. control < 150 min = 1.22). PNS activity was significantly increased in physically active subjects in the control group compared to that in the physically
inactive post-COVID-19 group (<150 min of MVPA).
These results were demonstrated through the RMSSD (ES post-COVID-19 < 150 min vs.
post-COVID-19 ≥ 150 min = 0.92; ES post-COVID-19 < 150 min vs. control < 150 min = 0.80),
pNN50 (ES post-COVID-19 < 150 min vs. post-COVID-19 ≥ 150 min = 1.16; ES postCOVID-19 < 150 min vs. control < 150 min = 0.71), and SD1 (ES post-COVID-19 < 150 min vs.
post-COVID-19 ≥ 150 min = 0.92; ES post-COVID-19 < 150 min vs. control < 150 min = 1.00)
indexes (p < 0.05).
Global variability was significantly reduced in the physically inactive post-COVID-19
group (<150 min of MVPA) when compared with that in the physically active patients in the
control group. These results can be observed in the SDNN (ES post-COVID-19 < 150 min vs.
post-COVID-19 ≥150 min = 0.83; ES post-COVID-19 < 150 min vs. control < 150 min = 0.69),
TINN (ES post-COVID-19 < 150 min vs. post-COVID-19 ≥ 150 min = 1.04; ES post-COVID-19 <
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150 min vs. control < 150 min = 0.82), and SD2 (ES COVID-19 < 150 min vs. post-COVID-19 ≥
150 min = 0.79; ES post-COVID-19 < 150 min vs. control < 150 min = 0.88) indexes (p < 0.05).
Table 4. Comparisons of HRV indexes between the post-COVID-19 and control groups according
to the physical activity levels. Data with normal distribution are expressed as mean and standard
deviation and data with non-normal distribution as median and 25–75% interquartile range.
Control Group
Groups
Variables
Sympathetic
activity
Mean HR
Stress index
LF (nu)
SNS index
Parasympathetic
activity
Mean RR
RMSSD
HF (nu)
pNN50
SD1 (ms)
PNS index
Global variability
SDNN
RR triangular
index
TINN
LF/HF
SD2 (ms)

≥150 min MVPA (n = 9)
Mean/
Median

Post-COVID-19

<150 min MVPA (n = 9)

SD/[IQR]

Mean/
Median

80.33
12.90
60.08
1.52

9.77
(10.70–15.20)
18.54
0.95

757.40
29.40
39.90
7.84
20.20
−1.32

≥150 min MVPA (n = 8)

SD/[IQR]

Mean/
Median

79.33
13.80
70.91
1.65

8.39
(12.50–16.65)
9.37
0.86

104.10
(25.95–35.45)
18.54
(5.76–14.85)
(18.40–25.15)
(−1.45–(−0.87))

763.40
24
29.08
3.95
17
−1

39.40

8.40

9.52

(8.13–10.46)

169.40
1.64
48.40

26.93
(1.06–3.30)
(43.80–58.75)

<150 min MVPA (n = 12)

SD/[IQR]

Mean/
Median

SD/[IQR]

p-Value

77.75
12.40
65.20
1.57

18.13
(11.33–14.73)
13.12
1.88

87.92
17.40
67.56
2.90

7.41
(15.68–23.15)
17.64
1.10

0.1755
0.0147 *
0.5058
0.374

78.92
(21.00–31.90)
9.37
(0.89–10.85)
(14.90–22.60)
(−1.62–(−0.86)

806.50
28.50
34.78
6.48
20.20
−0.87

178.10
(24.33–33.33)
13.11
(4.04–12.46)
(17.20–23.58)
(−1.79–(−0.13))

686.5
17.85
32.37
1.45
12.65
−1.82

59.63
(11.48–27.15)
17.63
(0.0–5.82)
(8.15–19.23)
(−2.17–(−1.33))

0.1113
0.0148 *
0.5044
0.0126 *
0.0155 *
0.317

32.94

10.07

33.54

8.14

26.19

9.27

0.0203 *

8.45

(6.94–8.97)

8.92

(8.10–10.23)

7.65

(4.97–8.40)

0.0509

153.20
2.61
43.70

41.47
(1.64–3.43)
(33.45–53.35)

157.90
1.49
46.65

35.25
(1.20–3.45)
(37.90–49.15)

119.80
2.67
34.25

38.02
(0.95–4.23)
(25.18–37.25)

0.0192 *
0.6431
0.0184 *

HR, heart rate; LF, low-frequency component; ms, millisecond; nu, normalized unit; SNS index, sympathetic
nervous system index; RMSSD, root mean square of differences between adjacent normal RR intervals in a time
interval; HF, high-frequency component; pNN50, percentage of adjacent RR intervals with a difference of duration
>50 ms; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term
intervals between consecutive heartbeats; PNS index, parasympathetic nervous system index; SDNN, standard
deviation of all normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
* Statistical significance (p < 0.05) between the control group with ≥150 min of MVPA and the post-COVID-19
group with <150 min of MVPA.

Additionally, the combination of overweight/obesity and low levels of physical activity was investigated to determine if it could impact the ANS in non-obese and physically
active individuals, as shown in Table 5. Identified participants who were overweight/obese
with an MVPA <150 min in the post-COVID-19 group presented significantly higher values
of sympathetic activity (p = 0.0149) compared with those in eutrophic participants with
an MVPA >150 min in the control group. Furthermore, parasympathetic activity and
global variability are notably reduced in participants who were overweight/obese with an
MVPA <150 min in the post-COVID-19 group.
Additionally, we performed a multivariable regression analysis, designed to test the
possibility of confounding relations of HRV with other clinically relevant independent
variables (BMI and physical activity levels). We identified that RMSSD (OR: 1.20; CI 95%:
0.98 to 1.48; p = 0.071), SD1 (OR: 0.86; CI 95%: 0.74 to 0.99; p= 0.045) and SD2 (OR: 0.93;
CI 95%: 0.87 to 0.99; p = 0.046) still held a significant association with post COVID-19
presence when adjusted for BMI (Appendix B).
When MVPA were included in the multivariable regression analysis model, only
SDNN (OR: 0.89; CI 95%: 0.80 to 1.00; p = 0.049 maintained significant association with
post COVID-19 presence, and the other HRV indexes held a significant association with
post-COVID-19 (p > 0.05), showing that MVPA might be a confounding outcome for
this investigation.
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Figure 4. Scatterplot of HRV indexes according to the physical activity levels. Data with normal distribution
are expressed as mean and standard deviation and data with non-normal distribution as median and
25–75% interquartile range. (A) Sympathetic nervous system activity; (B) parasympathetic nervous system
activity; (C) global variability. * Statistical significance (p < 0.05) between the control group with ≥150 min
of MVPA and the COVID-19 group with <150 min of MVPA. RMSSD, root mean square of differences
between adjacent normal RR intervals in a time interval; pNN50, percentage of adjacent RR intervals with
a difference of duration >50 ms; SD1, standard deviation of instantaneous beat-to-beat variability; SD2,
standard deviation of long-term intervals between consecutive heartbeats; SDNN, standard deviation of all
normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
Table 5. Comparison of HRV indexes between eutrophic and physically active subjects that presented
with both overweight/obesity status and low levels of physical activity in both groups. Data are
expressed as median and 25–75% interquartile range.
Control
Groups

Variables
Sympathetic
activity
Mean HR
Stress index
LF (nu)
SNS index
Parasympathetic
activity
Mean RR
RMSSD
HF (nu)
pNN50
SD1 (ms)
PNS index
Global variability
SDNN
RR triangular
index
TINN
LF/HF
SD2 (ms)

Non-obese + >150 min
MVPA
(n = 7)

Post-COVID-19

Ow/Ob + <150 min MVPA
(n = 6)

Non-obese + >150 min MVPA
(n = 4)

Ow/Ob + <150 min MVPA
(n = 8)

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

Mean/
Median

SD/[IQR]

p-Value

84
12.9
62.13
1.55

(75–87.00)
(10.80–15.70)
(41.57–72.84)
(0.92–2.52)

77.5
13.4
67.55
1.365

(70.75–81.00)
(12.70–16.25)
(60.43–80.16)
(1.14–1.92)

84.5
13.05
55.19
1.68

(63.50–94.25)
(11.98–14.73)
(51.51–58.73)
(0.41–2.71)

90
19.6
78.63
3.11

(82.50–91.00)
(15.68–23.80)
(48.76–86.92)
(2.05–4.00)

0.0772
0.0149 *
0.2434
0.0237 **

716
29.4
37.89
7.84
20.2
−1.32

(688.0–795.0)
(26.4–34.80)
(27.14–58.37)
(6.57–14.12)
(18.70–24.70)
(−1.410–(−0.98))

772.5
22.8
32.44
2.475
16.15
−0.975

(744.0–847.3)
(20.78–31.55)
(19.82–39.55)
(0.58–10.29)
(14.78–22.35)
(−1.41–(−0.90))

712
31.25
44.79
9.47
22.1
−1.275

(636.0–958.3)
(25.25–34.48)
(41.23–48.48)
(4.83–15.70)
(17.85–24.40)
(−1.798–(−0.025))

668.5
15.8
21.21
0.5
11.2
−1.825

(658.0–727.0)
9.95–27.15
(13.06–51.18)
(0.0–5.60)
(7.07–19.23)
(−2.17–(−1.33))

0.0659
0.0174 *
0.2434
0.0215 *
0.0174 *
0.5407

37.4

(33.40–44.10)

26.2

(23.98–39.80)

35.5

(31.93–41.33)

23.6

(17.13–27.88)

0.0128 *

9.52

(8.0–11.06)

8.09

(6.78–8.89)

8.92

(8.76–11.38)

6.81

(4.51–8.40)

0.0374 *

159
1.641
48.4

(148.0–194.0)
(0.71–2.68)
(43.80–56.80)

143
2.15
42

(117.5–179.0)
(1.53–4.31)
(32.63–53.33)

162.5
1.23
46.65

(148.0–198.8)
(1.06–1.42)
(1.67–2.68)

110.5
3.703
29.95

(75.75–132.3)
(0.95–7.06)
(23.10)

0.0123 *
0.2434
0.0198 *

HR, heart rate; LF, low-frequency component; ms, millisecond; nu, normalized unit; SNS index, sympathetic
nervous system index; RMSSD, root mean square of differences between adjacent normal RR intervals in a time
interval; HF, high-frequency component; pNN50, percentage of adjacent RR intervals with a difference of duration
>50 ms; SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term
intervals between consecutive heartbeats; PNS index, parasympathetic nervous system index; SDNN, standard
deviation of all normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
* Statistical significance (p < 0.05) between non-obese patients with >150 min MVPA in the control group and
overweight/obese patients with <150 min MVPA in the post-COVID-19 group. ** Statistical significance (p < 0.05)
between overweight/obese patients with <150 min MVPA in the control group and overweight/obese patients
with <150 min MVPA in the post-COVID-19 group.
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4. Discussion
This study analyzed if COVID-19 may affect the autonomic function of young adults
after mild and moderate infections. The relationship between BMI and physical activity
level with autonomic function was also investigated. Our main finding is that even in
mild and moderate infections, young adults who had COVID-19 had greater sympathetic
activity, less parasympathetic activity, and global variability when compared to that in
uninfected individuals. Moreover, in participants who were overweight and obese and/or
physically inactive, cardiac autonomic modulation showed worse indices. Collectively,
our study provides new insights regarding the role of BMI and physical activity status on
post-COVID-19-infection autonomic deregulation that may contribute to the understand of
pathophysiology and treatment of PACS.
Corroborating our findings, a recent study by Stute et al. [5] also showed that young
adults recovering from COVID-19 presented with autonomic dysregulation. The study
used an invasive method (muscle sympathetic nerve activity) in 16 subjects after COVID-19
infection, which contrasts with our study that showed similar results through HRV analysis, a simple, dependable, inexpensive, and noninvasive method [32]. Using wearable
sensor data, Radin and colleagues [44] reported a prolonged physiological impact of
SARS-CoV-2 infection, lasting approximately 2–3 months, on resting heart rate which may
reflect ANS dysfunction.
The prolonged alterations in autonomic function may be related to a persistent systemic inflammatory condition observed in post-viral stage. These findings may be attributed to the increased state of inflammation generated during COVID-19 infection, as
well as the direct infusion of inflammatory cytokines [8,9]. These mechanisms are often
characterized by marked increases in SNS activity [5,45]. The presence of markers of oxidative stress in COVID-19 and other viral diseases has been observed [8,46]. Therefore,
we believe that the oxidative stress and subsequent release of inflammatory cytokines
that accompany SARS-CoV-2 infection could explain the alterations in the ANS in young
subjects after COVID-19 in our study. Other factors explaining ANS alterations may also
be attributed to behavioral changes during and after infection, such as changes in physical
activity [47], nutritional status [48], and food and fluid consumption [49]. These conditions
also affect the blood volume (causing hypovolemia) and cardiovascular response [5].
This result highlights the urgency of assessments regarding the progression of COVID-19
in patients who have recovered, even if they are young or had mild or moderate symptoms, as an ANS dysregulation reveals a body homeostasis dysfunction and can predict
cardiovascular and metabolic illnesses and is directly correlated with mortality in several
diseases [10,50].
It is known that COVID-19 can affect different organs and systems at different magnitudes [6,45]. However, the impact of COVID-19 on the autonomic function of young
individuals and its relationship with the BMI and physical activity level are not yet well
established. Our findings revealed that patients who were overweight/obese in the postCOVID-19 group presented significantly lower parasympathetic activity and reduced
global variability compared to that in eutrophic individuals in the control group (Table 3
and Figure 3). Autonomic dysfunction after COVID-19 can be aggravated in individuals
with obesity, as studies previously showed that reduced HRV is associated with obesity and
inflammation [51]. The chronic low-grade inflammation caused by obesity [52], combined
with the cytokine storm response from the COVID-19 infection [9], may promote, and even
worsen, autonomic dysregulation in overweight/obese patients.
Our study showed that in physically active participants, cardiac autonomic modulation levels were better when compared to those in their inactive peers, even in participants
who had COVID-19. However, multivariable regression analysis showed vigorous physical
activity as a possible confounding factor, showing that the differences observed in HRV
might be primarily modulated by levels of physical activity and not by the presence of
post-COVID-19. It is known that exercise promotes positive adaptations in HRV parameters
in both control subjects and patients suffering from a variety of diseases [23,50]. Similarly,
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both exercise training and physical activity habits improve heart rate variability parameters, the autonomic profile, and arterial compliance, as well as the baroreflex sensitivity
in HIV+ patients, highlighting the impact of lifestyle habits to modulate ANS in viral
conditions [53,54].
Regular exercise can promote functional and structural changes in the central and
peripheral mechanisms of the cardiovascular system to ensure proper blood perfusion
and cardiac response according to metabolic demands [55]. There is a consistent body of
evidence stating that exercise increases resting vagal activity and induces neuronal plasticity
in central autonomic networks. It is suggested that these mechanisms are mainly related
to improved control of the nucleus tractus solitarii, rostral ventrolateral medulla, and
paraventricular nucleus of the hypothalamus [55,56]. The previous autonomic adaptations
in physically active individuals may explain the protective role of exercise observed after
COVID-19 infection.
Post-viral conditions, such as chronic fatigue syndrome, are characterized by autonomic dysfunction that strongly interfere in the health quality and neurocognitive aspects
of the patients. Physical activity is a consistent predictor of the measure of autonomic
function in chronic fatigue syndrome patients, predicting 45% of the variance in the resting
HR, 36% of the variance in the sitting HR, 20% of the variance in standing HR, 20% of the
variance in HR on tilt, and 56% of the variance in the SBP fall in phase II of the Valsalva
maneuver [20].
On the other hand, associations between low levels of moderate- to high-intensity
physical activity patterns with resting HR and reduced HRV were previously reported in
chronic fatigue syndrome patients, suggesting that reduction in physical activity can, in
part, be explained by autonomic dysfunction but not fatigue severity [57]. Here, we report
that post COVID-19 patients had significantly low levels of vigorous physical activity that
may be related to the imbalance in ANS dysfunction.
Additionally, this study revealed that the number of symptoms reported by patients
during the course of the COVID-19 infection was associated with the HRV response. These
data may be explained by the severity of the virus infection that will usually promote more
severe symptoms, consequently affecting levels of inflammation and oxidative stress [3,8],
mediating changes in the HRV [58].
The main limitations to our investigation were (1) the cross-sectional nature of the
study and the small sample size (n = 57). This is of particular concern because our primary
outcome measure (HRV) is characterized by high interindividual variability. (2) Despite
matching for age and BMI, groups were not similar regarding physical activity. The postCOVID-19 group was less active, probably due to the symptoms and indisposition related
to the infection, which can generate a confounding bias. Therefore, longitudinal designs
monitoring healthy young subjects recovering from SARS-CoV-2 infection are undoubtedly
warranted to better understand the impact of the virus on ANS activity.
This study also presents several strengths. First, young subjects with post mild and
moderate COVID-19 infection were investigated, a commonly overlooked population in
recent studies. Second, to our knowledge, this is the first study to investigate the influence
of the BMI and physical activity level on the ANS after COVID-19. Third, our results are of
great clinical relevance as they show the importance of screening and monitoring in young
adults, especially those who are overweight/obese or physically inactive. Finally, in our
study, the practice of physical activity was measured using accelerometry, which provides
more reliable information about the intensity of physical activity, as self-reports may be
susceptible to memory bias.
As practical applications of the present study, the importance of maintaining the BMI
close to eutrophic levels and the consistent practice of physical activity is highlighted,
even in the time of a pandemic where social isolation may be necessary (considering all
precautions, for example, when performing outdoor physical activities).
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5. Conclusions
Mild to moderate SARS-CoV-2 infection promotes changes in the ANS of young adults
that persist one month after the acute phase of the disease. Additionally, the BMI can
modulate the changes in the ANS after COVID-19 in different perspectives: excessive BMI
accentuates the changes in the ANS. Finally, the severity of the symptomatology maintained
after the SARS-CoV-2 infection may also have important consequences on the daily life
activities and ability to perform physical activities, thus additionally contributing to the
autonomic balance of these individuals.
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Appendix A
Table A1. Results of binary logistic regression analysis of HRV indexes as a predictor of post COVID-19.
Variables
Sympathetic nervous system activity
Stress index
Parasympathetic nervous system activity
RMSSD
pNN50
SD1 (ms)
Global variability
SDNN
TINN
SD2 (ms)

Odds Ratio

95% CI

p Value

1.22

1.00 to 1.48

0.041 *

0.89
0.88
0.85

0.81 to 0.98
0.78 to 1.00
0.74 to 0.98

0.026 *
0.068
0.027 *

0.92
0.98
0.93

0.85 to 0.99
0.96 to 1.00
0.87 to 0.99

0.039 *
0.051
0.024 *

Ms, millisecond; nu, normalized unit; RMSSD, root mean square of differences between adjacent normal RR
intervals in a time interval; pNN50, percentage of adjacent RR intervals with a difference in duration >50 ms;
SD1, standard deviation of instantaneous beat-to-beat variability; SD2, standard deviation of long-term intervals
between consecutive heartbeats; SDNN, standard deviation of all normal RR intervals recorded in a time interval;
TINN, triangular interpolation of NN interval. * Statistical significance (p < 0.05) between post-COVID-19 and
control group.
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Appendix B
Table A2. Results of multiple logistic regression considering the presence of post-COVID-19 and
confounding relations with independent variables (BMI and physical activity) on HRV indexes.
Body Mass Index (BMI)

Sympathetic activity
Stress index
BMI

MVPA

Odds
Ratio

95% CI

p Value

1.20
1.03

0.98 to 1.48
0.88 to 1.20

0.071
0.692

0.90
1.02
0.90
1.05
0.86
1.02

0.81 to 0.99
0.88 to 1.20
0.79 to 1.02
0.91 to 1.21
0.74 to 0.99
0.88 to 1.20

0.044 *
0.713
0.112
0.493
0.045 *
0.711

0.92
1.02
0.98
1.03
0.93
1.01

0.85 to 1.00
0.87 to 1.19
0.96 to 1.00
0.88 to 1.20
0.87 to 0.99
0.86 to 1.19

0.080
0.752
0.103
0.691
0.046 *
0.829

Parasympathetic activity
RMSSD
BMI
pNN50
BMI
SD1 (ms)
BMI
Global variability
SDNN
BMI
TINN
BMI
SD2 (ms)
BMI

Sympathetic activity
Stress index
MVPA
Parasympathetic
activity
RMSSD
MVPA
pNN50
MVPA
SD1 (ms)
MVPA
Global variability
SDNN
MVPA
TINN
MVPA
SD2 (ms)
MVPA

Odds
Ratio

95% CI

p Value

1.25
1.00

0.97 to 1.61
0.97 to 1.03

0.082
0.919

0.88
1.00
0.88
0.99
0.84
1.00

0.78 to 1.00
0.97 to 1.03
0.75 to 1.03
0.97 to 1.02
0.70 to 1.00
0.97 to 1.03

0.060
0.850
0.125
0.951
0.062
0.852

0.89
1.00
0.97
1.00
0.97
0.98

0.80 to 1.00
0.97 to 1.03
0.95 to 1.00
0.97 to 1.03
0.89 to 1.06
0.96 to 1.01

0.049 *
0.876
0.098
0.965
0.601
0.409

BMI: Body Mass iNEX; MVPA, moderate to vigorous physical activities; CI, confidence interval. RMSSD, root
mean square of differences between adjacent normal RR intervals in a time interval; pNN50, percentage of
adjacent RR intervals with a difference in duration >50 ms; SD1, standard deviation of instantaneous beat-to-beat
variability; SD2, standard deviation of long-term intervals between consecutive heartbeats; SDNN, standard
deviation of all normal RR intervals recorded in a time interval; TINN, triangular interpolation of NN interval.
* Statistical significance (p < 0.05).

Correlations were also evaluated, and a linear regression was performed between the
numbers of symptoms reported by patients during the course of the COVID-19 infection
and HRV indexes. In these analyses, significant results were identified for LF (β = 0.075;
95% CI = 0.002 to 0.14; r2 = 0.20; p = 0.046); HF (β = 0.075; 95% CI = −0.149 to −0.002;
r2 = 0.204; p = 0.046), and LF/HF components in normalized units (β = 0.48; 95% CI = 0.052
to 0.90, r2 = 0.23; p = 0.030).
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